Showing results (121-130 of 185) with videos related to

Sort By:
Pageof 19
Haematologica|March 5, 2026
Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVDJiayu Yang, Diego Villa, Alina S Gerrie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern eraAlden A Moccia, Jane Donaldson, Mukesh Chhanabhai, et al.
British Journal of Haematology|October 22, 2016
Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experienceGreg Hapgood, Tom Pickles, Laurie H Sehn, et al.
Blood Advances|December 6, 2019
Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarrayDiego Villa, King L Tan, Christian Steidl, et al.
Differentiation; Research in Biological Diversity|November 23, 2016
Hnf4α is a key gene that can generate columnar metaplasia in oesophageal epitheliumBenjamin J Colleypriest, Zoë D Burke, Leonard P Griffiths, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Leukemia|December 23, 2011
BCL2 mutations in diffuse large B-cell lymphomaJ M Schuetz, N A Johnson, R D Morin, et al.
British Journal of Haematology|February 19, 2020
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorderMichael D Jain, Ryan Lam, Zhihui Liu, et al.
British Journal of Haematology|November 8, 2024
Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative casesJ L Kim, D Villa, R P Tonseth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British ColumbiaGreg Hapgood, Yvonne Zheng, Laurie H Sehn, et al.
Pageof 19